Benzinga -
- RBC Capital Markets downgraded Medtronic Plc (NYSE: NYSE:MDT) from Outperform to Sector Perform and cut its price target to $89 from $102, citing mixed sentiments for the stock.
- The analyst notes investor disappointment regarding management's execution on several fronts, including warning letter, supply impact, RDN, slower pace of recovery, and persistent macro headwinds.
- The company lowered its FY23 organic growth outlook due to supply constraints and slower recovery in certain sub-segments.
- Related: Medtronic Trims FY23 Annual Outlook On Currency Headwind, Posts Mixed Q2 Earnings.
- While the RDN opportunity is still intact, it will take longer to accrue sales as it may/may not require an FDA Panel in 1H'CY23 to get approval, followed by reimbursement, both of which could take well over a year.
- Secondly, Medtronic will have to get an indication-by-indication approval for Hugo as supply constraints hit the U.S. study.
- The analyst notes that the urology indication is among the mature robotic procedure categories.
- Price Action: MDT shares are down 4.07% at $77.61 on the last check Monday.
| Feb 2022 | Credit Suisse (SIX:CSGN) | Maintains | Outperform | |
| Feb 2022 | Needham | Maintains | Buy | |
| Feb 2022 | Raymond James | Maintains | Outperform |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.